FGFR3 and urothelial carcinoma: These mutations which occur at the level of genome, are technologically difficult to detect in the routine laboratory (4), therefore, this study was conducted to analyze the immunohistochemical expression of FGFR3 in urothelial carcinoma and correlate the FGFR3 expression with the pathological stage, recurrence and other clinicopathological parameters.